Convergent Antibody Responses to SARS-CoV-2 Infection in Convalescent Individuals
Davide F. Robbiani; Christian Gaebler; Frauke Muecksch; Julio Cetrulo Lorenzi; Zijun Wang; Alice Cho; Marianna Agudelo; Christopher Barnes; Shlomo Finkin; Thomas Hagglof; Thiago Oliveira; Charlotte Viant; Arlene Hurley; Katrina Millard; Rhonda Kost; Melissa Cipolla; Anna Gazumyan; Kristie Gordon; Filippo Bianchini; Spencer Chen; Victor Ramos; Roshni Patel; Juan Dizon; Irina Shimeliovich; Pilar Mendoza; Harald Hartweger; Lilian Nogueira; Maggi Pack; Jill Horowitz; Fabian Schmidt; Yiska Weisblum; Hans-Heinrich Hoffmann; Eleftherios Michailidis; Alison Ashbrook; Eric F. Waltari; John Pak; Kathryn Huey-Tubman; Nicholas Koranda; Pauline Hoffman; Anthony West; Charles Rice; Theodora Hatziioannou; Pamela Bjorkman; Paul Bieniasz; Marina Caskey; Michel Nussenzweig.
Preprint
en Inglés
| PREPRINT-BIORXIV | ID: ppbiorxiv-092619
During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives. Virus entry into cells depends on the receptor binding domain (RBD) of the SARS-CoV-2 spike protein (S). Although there is no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19 convalescent individuals. Plasmas collected an average of 39 days after the onset of symptoms had variable half-maximal neutralizing titers ranging from undetectable in 33% to below 11000 in 79%, while only 1% showed titers >15000. Antibody cloning revealed expanded clones of RBD-specific memory B cells expressing closely related antibodies in different individuals. Despite low plasma titers, antibodies to three distinct epitopes on RBD neutralized at half-maximal inhibitory concentrations (IC50s) as low as single digit ng/mL. Thus, most convalescent plasmas obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Texto completo
Documentos relacionados